You Demand Data on Everything Except This
Think about the last significant decision you made at work. A hire, an investment, a strategic pivot. You almost certainly had data. Financial projections, track records, market analysis, a thesis you could argue and defend. You probably spent more time stress-testing that decision than you spent on anything else that week.
Now think about the last time you had a comprehensive look at your own biology.
Not a quick blood pressure check at the GP. Not the five values from your Check-up 35, which were "all fine." A real look at cardiovascular particle counts, metabolic function, hormonal status, inflammatory load. The actual numbers that determine whether the hardware running all those decisions is operating at full capacity, slowly degrading, or quietly accumulating risk that won't show symptoms for another decade.
For most executives aged 35 to 55, the answer is: never. The same rigour applied to a €50,000 investment decision has never been applied to the biological platform making that decision. That is not a lifestyle observation. It is a measurement gap. Measurement gaps, in any domain, have consequences.
"Nothing Is Obviously Wrong" Is Not the Same as "Everything Is Optimal"
There is an important distinction between disease detection and performance monitoring. Your GP's job, and the statutory healthcare system's design, is the former. The Gesundheits-Check-up, Germany's standard preventive health entitlement, was built to catch clinical disease in symptomatic patients. Five values, every three years from age 35. It is a disease screening tool. It was never designed to tell you whether you are performing at your best, whether your cardiovascular risk is accumulating silently, or whether the cognitive output you rely on every day is being quietly compromised by markers nobody has measured.
"Nothing is obviously wrong" and "everything is optimal" are not the same statement. One is the absence of a diagnosis. The other is something you can only say when you have actually looked.
What Your Hausarzt Is Actually Measuring (And Why That's Not Enough)
This is not a criticism of German GPs. They are working within a system designed for a specific purpose, and within the constraints of that system, which include an average consultation time of roughly seven minutes and reimbursement structures tied to clinical indication, they are doing exactly what the system asks of them.
The statutory Gesundheits-Check-up includes a lipid profile (total cholesterol, LDL, HDL, triglycerides) and a fasting glucose reading. That is it. No thyroid. No iron. No inflammation markers. No hormonal assessment. No metabolic depth beyond a blood sugar snapshot. Five values, reviewed in a brief consultation, against reference ranges calibrated to the general population, not to what optimal looks like for a high-functioning adult who wants to stay that way.
If you ask for more, and many health-conscious patients do, your GP can order additional markers as an individuelle Gesundheitsleistung (IGeL), at your own expense, based on their clinical judgement of what is relevant. The marker selection depends on the individual GP. The interpretation is typically limited to "normal" or "abnormal." The context that makes the numbers meaningful is rarely provided.
The Markers That Would Change Your Decisions, and Aren't on the List
The biomarkers most relevant to executive health, such as cardiovascular particle counts, insulin sensitivity, hormonal balance and inflammatory load, are almost entirely absent from standard care. Fasting insulin is not on the Check-up 35. ApoB is not on the Check-up 35. hsCRP is not on the Check-up 35. Free testosterone is not on the Check-up 35. Lp(a), the genetic cardiovascular risk factor carried by roughly one in five Europeans, has almost certainly never been tested in you if your only health monitoring has been the statutory system.
These are not obscure, experimental markers. They are among the most clinically validated predictive biomarkers in preventive medicine, and they are simply not part of what routine care offers. Our guide to the großes Blutbild maps the full extent of this gap in the German context.
Aniva tests 100+ biomarkers, including every marker discussed in this article, at an ISO 15189-certified German laboratory, for €199/year. That is less than most private GP consultation fees. Get started with Aniva →
Your Cardiovascular Risk Probably Isn't What Your Cholesterol Says It Is
Here is something worth sitting with. Total LDL cholesterol may be the single most misleading data point in mainstream preventive medicine. It is the number your GP shows you, the one that appears on every check-up printout, the one the entire "healthy cholesterol" conversation revolves around.
Not because cholesterol doesn't matter. It does. But because LDL-C measures the mass of cholesterol in your blood, not the number of particles carrying it. And it is particles, specifically the number of ApoB-containing particles transiting through your arterial walls, that determine your actual atherogenic risk. Two people can have identical LDL-C readings and wildly different cardiovascular trajectories, because one has fewer, larger particles and the other has more, smaller ones. The mass is the same. The particle count is not. And the particle count is what matters.
ApoB: Why the European Society of Cardiology Switched to Counting Particles
The European Society of Cardiology's 2021 cardiovascular prevention guidelines now recommend ApoB as the preferred marker for assessing cardiovascular risk, specifically over LDL-C, in patients with metabolic syndrome, insulin resistance, or diabetes, where LDL-C is most likely to underestimate true risk. [1] The reasoning is mechanistic: every single atherogenic particle, whether LDL, VLDL, IDL or Lp(a), carries exactly one ApoB molecule. Counting ApoB counts the particles. Measuring LDL-C does not.
The practical implication: someone can have a "normal" LDL-C of 115 mg/dL, feel reassured by their check-up, and simultaneously carry an ApoB burden that substantially elevates their long-term cardiovascular risk. Most cardiovascular events in seemingly healthy middle-aged adults originate in that gap between what the standard test shows and what the risk actually is.
hsCRP and the Inflammation You Can't Feel
Atherosclerosis is not just a plumbing problem. It is an inflammatory disease. The plaques that rupture and cause heart attacks are, characteristically, inflamed plaques, destabilised by immune cell infiltration and inflammatory signalling. And high-sensitivity C-reactive protein (hsCRP) is the most clinically validated measure of that background inflammatory load.
The data on hsCRP and long-term cardiovascular outcomes is substantial and consistent. A landmark study in the New England Journal of Medicine following 27,939 initially healthy women for 30 years found that baseline hsCRP was a stronger predictor of cardiovascular events than LDL-C, and that each biomarker provided additive information to the others, such that measuring all three (hsCRP, LDL-C, and Lp(a)) together produced the greatest spread in long-term risk stratification. [2] That is not a small study. That is three decades of prospective follow-up.
What makes hsCRP clinically uncomfortable is that it is entirely silent. No symptoms. No subjective signal. An elevated hsCRP at 3.5 mg/L produces no warning that would prompt a GP visit, and yet it predicts major adverse cardiovascular events over a 20-year horizon as reliably as many traditional risk factors. The American College of Cardiology's 2025 Scientific Statement now recommends universal hsCRP screening in both primary and secondary cardiovascular prevention. [3] That recommendation has not yet filtered into routine German primary care.
Lp(a): The Genetic Risk Factor Nobody Told You About
Lipoprotein(a), abbreviated Lp(a), is an LDL-like particle with an additional protein attached. Elevated Lp(a) increases the risk of myocardial infarction, stroke, and aortic valve disease, independently of every other risk factor. It does not respond meaningfully to diet, exercise, or standard lipid-lowering therapy. It is genetically determined. And roughly 20% of Europeans carry elevated Lp(a). [4]
Here is the thing: you only need to test it once. Because it doesn't change. But if you have never tested it, you do not know whether you are in that 20%. You cannot manage risk you haven't measured. Our article on cholesterol, ApoB, and Lp(a) covers the full picture of what advanced lipid testing actually looks like.
The Afternoon Slump Isn't a Caffeine Problem
You know the pattern. Sharp enough at 9am. Clear through a productive morning. Then, somewhere between 2pm and 4pm, the quality of your thinking changes. Not dramatically, you're still functioning, but the sharpness is gone. Problems feel harder. Decisions feel heavier. You reach for the third coffee not because you need it but because you need something.
Most executives attribute this to workload, sleep debt, or a slow afternoon. The less comfortable explanation is that it is often a metabolic signalling problem, and specifically that your insulin response to food may be quietly dysregulated in a way that a standard fasting glucose test would never catch.
Insulin Resistance Starts Years Before Your Blood Sugar Moves
Insulin resistance is not a binary condition that switches on when your GP diagnoses pre-diabetes. It is a spectrum, and it develops over years, sometimes a decade or more, before fasting glucose rises enough to trigger any clinical flag.
The mechanism: as cells become progressively less sensitive to insulin signals, the pancreas compensates by producing more. Glucose stays controlled, because the pancreas is working harder to keep it there. On a standard metabolic panel, everything looks normal. But fasting insulin is elevated. And elevated fasting insulin drives the post-meal glucose volatility that produces energy crashes, carbohydrate cravings, abdominal fat accumulation, and the kind of mid-afternoon cognitive degradation that feels like tiredness but is actually dysregulated fuel supply to the brain.
Optimal fasting insulin: under 8 µIU/mL. The standard laboratory "normal" upper limit: up to 25 µIU/mL. That 17-point gap is where metabolic dysfunction lives, undetected, for years. Insulin resistance is now thought to affect roughly one-third of adults globally, and the majority have no idea, because the test that catches it is not on the standard metabolic panel. [5] Our article on blood sugar and metabolic health explores this in depth.
HbA1c Alone Is Like a Sales Figure Without the Margin
HbA1c, the three-month blood sugar average, is a valuable marker. But it is a late signal. It reflects what has already happened to your glucose control over the past 90 days, averaged across all conditions. It does not tell you what your insulin is doing. It does not tell you whether you have a glucose spike and crash pattern after lunch. It does not catch insulin resistance at Stage 1, before glucose dysregulation is established enough to show up in the average.
Fasting insulin catches Stage 1. HbA1c catches Stage 2 or 3. The clinical objective, especially for someone who wants to maintain cognitive and physical output for the next 20 years, is to intervene at Stage 1. That means testing fasting insulin as a standard part of any metabolic assessment, not as an afterthought when the HbA1c starts to climb.
Aniva includes fasting insulin, HbA1c, and fasting glucose as standard markers, giving you the full metabolic picture rather than a single delayed snapshot. See the full biomarker list →
Your Cortisol Isn't Necessarily Too High. It May Be Broken.
The popular narrative about executive stress and cortisol is almost always the same: you're running too hard, your cortisol is chronically elevated, you need to slow down. Sometimes that's accurate. But it's not the most interesting version of the story, and it's often not the correct one.
For a significant proportion of people who have been operating under chronic high pressure for years, the more accurate picture is not elevated cortisol. It is a flattened cortisol rhythm, a once-functional diurnal curve that has lost its shape. Not too high. Miscalibrated.
Why a Single Cortisol Blood Test Tells You Almost Nothing
Cortisol is not a static hormone. It is a rhythm. Under healthy conditions, it spikes sharply in the 30 to 45 minutes after waking, the cortisol awakening response, then declines steadily through the day, reaching a nadir around midnight. That rhythm drives your alertness, your immune regulation, your anti-inflammatory response, and your metabolic function.
A single cortisol blood test captures one moment on that 24-hour curve. It tells you where cortisol was at 8:47am on a Tuesday. It tells you almost nothing about whether the rhythm is intact. Someone with a completely dysregulated cortisol pattern, flat in the morning and paradoxically elevated at night, can produce a single mid-morning reading that appears perfectly normal. Our cortisol deep-dive explains the full picture of what a healthy versus disrupted diurnal pattern looks like.
Chronic Cortisol Dysregulation and the Prefrontal Cortex
The prefrontal cortex, which is the brain region responsible for complex decision-making, working memory, cognitive flexibility, and impulse control, is disproportionately vulnerable to the effects of chronic stress and cortisol dysregulation. This is not a vague claim. The mechanisms are well established: chronic glucocorticoid exposure produces morphological changes in prefrontal dendritic architecture, impairs dopamine signalling in PFC circuits, and reduces the cognitive flexibility required for adaptive, high-quality decision-making. [6]
A 2024 review in Neuropharmacology synthesising the literature on chronic stress and executive function found consistent impairments across three domains: cognitive flexibility, working memory, and behavioural inhibition. These are precisely the cognitive tools that make the difference between a good decision and a poor one under pressure. [7] The effect is not dramatic and sudden. It is subtle, cumulative, and easy to rationalise as fatigue or overwork. Until you measure it.
DHEA-S: The Counter-Regulatory Marker Everyone Forgets
DHEA-S (dehydroepiandrosterone sulphate) is cortisol's functional counterpart. Under healthy conditions, it is produced in abundance and acts as a buffer, a counter-regulatory hormone that moderates the effects of cortisol on tissue and cognition. Under chronic stress, DHEA-S tends to decline as cortisol remains dysregulated. The ratio between the two is clinically meaningful: a low DHEA-S in the context of an abnormal cortisol pattern is a more specific signal of HPA axis strain than either marker in isolation. Most standard panels measure cortisol alone, missing half of the picture.
Testosterone Doesn't Fall Off a Cliff. It Erodes.
There is a reason the low-T conversation makes many men, especially professionally successful ones, deeply uncomfortable. It sounds like a deficit. A failure. A problem to be medicated away. That framing is unhelpful and mostly inaccurate.
The more honest version of the story is about gradual erosion. Research consistently shows that total serum testosterone in men begins to decline from age 35, and that free testosterone, the fraction not bound to sex hormone-binding globulin (SHBG) and therefore biologically available, declines at approximately 1.3% per year from the mid-thirties onward. [8] That is not a cliff. It is a slope. And slopes are almost imperceptible in real time, which is precisely why so many men in their mid-forties feel different from their mid-thirties selves without being able to identify when or why the change began.
Total T vs. Free T: Why the Number Your Doctor Shows You May Be Irrelevant
When a GP tests testosterone, they typically measure total testosterone. This is not the number that matters.
Up to 98% of testosterone in circulation is bound to proteins, primarily SHBG and albumin. Only the unbound fraction, free testosterone, is biologically active. Your cells cannot use what is locked. And SHBG, the primary binding protein, is raised by caloric restriction, chronic fasting, liver stress, hyperthyroidism, and ageing itself. The result: a man can have a perfectly "normal" total testosterone reading of 600 ng/dL and simultaneously have functionally low free testosterone because his SHBG is elevated, locking away the bulk of it.
His GP looks at the total T number, sees no problem, and moves on. The patient continues to experience the fatigue, reduced motivation, slower recovery, and muted cognitive drive that brought him in. The measurement was technically correct. The interpretation was incomplete.
The Cognitive Dimension Nobody Mentions
Testosterone's role in male cognition is underappreciated in the clinical conversation, which tends to focus narrowly on libido and muscle mass. But epidemiological studies of middle-aged and older men consistently associate lower testosterone concentrations with reduced verbal memory, attenuated processing speed, and decreased executive function. [9] This is not about dramatic decline; it is about the marginal differences in cognitive sharpness and motivational drive that compound over years, the slow grading-down of what you are capable of, that are easy to attribute to age, stress, or circumstance rather than a measurable, potentially addressable hormonal shift.
To be direct: testosterone replacement therapy is a medical decision that requires clinical oversight and a detailed risk-benefit assessment. That is not what this article is advocating. What it is advocating is knowing your numbers, meaning total T, free T, and SHBG together, so that if there is a drift, you can see it, contextualise it, and make an informed decision about what, if anything, to do.
The BGF Angle: How This Becomes a Company Conversation
If you are reading this as an individual, the personal case is straightforward. But if you sit in a leadership, HR, or C-suite role, there is a second conversation worth having, one that reframes comprehensive health monitoring from a personal luxury to a structural investment.
Germany's betriebliche Gesundheitsförderung (BGF) framework, governed under §20b SGB V, allows employers to invest up to €600 per employee per year in certified preventive health measures, tax-free. The intent of the legislation is exactly what the name suggests: workplace health promotion, upstream of disease, before the system is needed. [10]
In practice, most BGF budgets flow towards yoga courses, ergonomic assessments, and mental health webinars. These have value. But they do not catch a cardiovascular event building silently in a 47-year-old senior manager. They do not identify the insulin resistance that has been suppressing a department head's cognitive output for three years. They do not provide the biological baseline that would actually change the trajectory of health outcomes for the people an organisation depends on most.
What "Preventive" Actually Means in a Corporate Context
The economics of executive health failure are rarely calculated explicitly, but they are substantial. A senior leader's unplanned absence, whether through burnout, cardiovascular event, or metabolic crisis, carries costs that extend well beyond sick days: leadership continuity, decision-making gaps, team performance, and institutional knowledge. The average cost of replacing a senior executive is typically estimated at 6 to 9 months of their salary, before productivity losses during transition.
Against that backdrop, the cost of annual comprehensive biomarker testing is not a wellness expense. It is a risk management investment, one that, unlike most risk management expenditure, has a non-zero chance of changing the outcome.
Aniva as a BGF-Compatible Benefit
Aniva's annual health panel, with 100+ biomarkers, an ISO 15189-certified German laboratory, and a personalised report and action plan, maps directly onto the preventive intent of the BGF framework. For employers looking to extend their corporate health benefit beyond the standard offerings, or for HR leaders building a more substantive employee wellbeing proposition, comprehensive biomarker testing at €199/year per person represents one of the highest-information investments available per euro spent.
For companies interested in a BGF-aligned group arrangement, or for individuals who want to start with their own baseline: apply for Aniva membership →
What the Panel Actually Looks Like
An executive health panel built for the 35 to 55 age group should cover four domains comprehensively. This is what Aniva's panel includes across each:
Cardiovascular risk: Full lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), ApoB, Lp(a), homocysteine, hsCRP. This is the full picture of atherogenic risk, not just the cholesterol mass, but the particle burden, the inflammatory load, and the genetic wildcard.
Metabolic health: Fasting glucose, HbA1c, fasting insulin, HOMA-IR. The four-marker metabolic profile that catches insulin resistance at Stage 1, not Stage 3. Liver function markers (AST, ALT, GGT) and kidney function (creatinine, eGFR, urea, uric acid) complete the organ health picture.
Hormonal status: Total testosterone, free testosterone (calculated), SHBG, cortisol, DHEA-S, thyroid panel (TSH, free T3, free T4, TPO antibodies). This is the hormonal context that explains energy, recovery, cognitive drive, and stress resilience, and that a standard GP panel almost never assesses in full.
Nutritional and inflammatory markers: Vitamin D, B12, folate, ferritin, serum iron, magnesium, zinc, hs-CRP. The nutrient depletions that produce the kind of low-grade, difficult-to-diagnose underperformance that is easy to attribute to ageing or workload, and that are, in many cases, quietly fixable once you can see them.
Plus the full großes Blutbild, because yes, that is included too, as one component of the panel rather than the whole thing.
The Audit You Haven't Run Yet
You did not build a career on instinct alone. You built it on information, on knowing your numbers, understanding the landscape, identifying risk before it became a problem. The same logic applies here.
Your cardiovascular risk is not your LDL-C number. It is the interplay of ApoB, hsCRP, Lp(a), and metabolic function, most of which you have never measured. Your cognitive output is not just a function of sleep and workload. It is shaped by cortisol rhythm, insulin sensitivity, testosterone, and a dozen nutritional variables that no one has ever mapped for you. Your energy is not random. It is data.
The most expensive asset you manage is the one running all the others. It deserves at least the same standard of analysis you would apply to anything else.
Aniva tests 100+ biomarkers annually, covering cardiovascular, metabolic, hormonal and inflammatory markers, at a certified German laboratory, with a personalised report and action plan, for €199/year. One blood draw. One complete picture. Apply for membership →
Sources
[1] Visseren FLJ, et al. "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice." European Heart Journal, 2021;42(34):3227-3337. https://academic.oup.com/eurheartj/article/42/34/3227/6358713
[2] Ridker PM, et al. "Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women." New England Journal of Medicine, 2024. https://www.nejm.org/doi/10.1056/NEJMoa2405302
[3] American College of Cardiology. "hsCRP: A Promising Risk Assessment Tool." ACC Scientific Statement, 2025. https://www.acc.org/latest-in-cardiology/articles/2025/12/01/01/prioritizing-health-hscrp
[4] Tsimikas S, et al. "High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)." Journal of the American College of Cardiology, 2021. https://www.jacc.org/doi/10.1016/j.jacc.2021.07.016
[5] Dorcely B, et al. "Insulin Resistance." In: StatPearls. National Library of Medicine, 2023. https://www.ncbi.nlm.nih.gov/books/NBK507839/
[6] Cerqueira JJ, et al. "Prefrontal cortex executive processes affected by stress in health and disease." Frontiers in Psychiatry, 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5756532/
[7] Bhatt S, et al. "Effects of chronic stress on cognitive function." Neuropharmacology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11407068/
[8] Ye M, et al. "Age-related testosterone decline: mechanisms and intervention strategies." Reproductive Biology and Endocrinology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11562514/
[9] Gillett M, et al. "Testosterone, cognitive decline and dementia in ageing men." PMC, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9789006/
[10] Bundesministerium für Gesundheit. "Betriebliche Gesundheitsförderung." bundesgesundheitsministerium.de. Accessed March 2026. https://www.bundesgesundheitsministerium.de/themen/praevention/betriebliche-gesundheitsfoerderung
[11] European Atherosclerosis Society. "Lipoprotein(a) as a cardiovascular risk factor: current status." European Heart Journal, 2010;31(23):2844-2853. https://academic.oup.com/eurheartj/article/31/23/2844/2398038
[12] ASCOT Legacy Study. "Baseline hsCRP with incident cardiovascular events and all-cause mortality over 20 years." eBioMedicine / The Lancet, 2025. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00230-0/fulltext
[13] Gemeinsamer Bundesausschuss (G-BA). "Gesundheitsuntersuchungs-Richtlinie." g-ba.de. Accessed March 2026.
This article is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. Hormonal markers, metabolic findings, and cardiovascular risk factors discussed here require interpretation in the context of your individual health history by a qualified healthcare professional. If you have specific health concerns, please consult your doctor or a licensed medical practitioner. Aniva Health does not provide medical diagnoses or treatment recommendations.
